Since 2003, the Lilly MDR-TB Partnership has aimed to prevent and treat multidrug-resistant tuberculosis (MDR-TB), a disease with nearly half a million new cases every year. Despite terminating production of its two TB drugs in 2011, Lilly remains committed to the Lilly MDR-TB Partnership through 2017, focusing on the four countries with the highest MDR-TB disease burden.

Besides our work in our four focus countries, we work with a number of global partners to train nurses, support infection control efforts and provide community support in a number of other countries.

Our Global Partners

International Council of Nurses: Global project management for training of nurse trainers and operation of wellness centers
International Federation of Red Cross and Red Crescent Societies: Support patient treatment adherence support programs
World Health Organization: Promote and help implement initiatives to strengthen private sector capacity for improved TB care delivery
Stop TB Partnership: Improved advocacy and awareness

Drug Supply and Access

Too few MDR-TB patients globally receive appropriate second-line treatment. Drug supply and access is an area that Lilly has unique and deep experience in, and focused support for a concentrated global effort is critical to the ultimate success of the technology transfer work carried out under the auspices of the Lilly MDR-TB Partnership.